# Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

> **NCT00192192** · PHASE3 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 20 (—)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** CAIV-T

## Key facts

- **NCT ID:** NCT00192192
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** 2000-12
- **Target enrollment:** 20 (—)
- **Last updated:** 2021-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192192, "Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00192192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*